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Abstract
Persistent infection with high- risk human papillomaviruses (HR- HPVs) is the causal factor in over 99 % of cervical cancer cases, 
and a significant proportion of oropharyngeal and anogenital cancers. The key drivers of HPV- mediated transformation are the 
oncoproteins E5, E6 and E7. Together, they act to prolong cell- cycle progression, delay differentiation and inhibit apoptosis in 
the host keratinocyte cell in order to generate an environment permissive for viral replication. The oncoproteins also have key 
roles in mediating evasion of the host immune response, enabling infection to persist. Moreover, prolonged infection within the 
cellular environment established by the HR- HPV oncoproteins can lead to the acquisition of host genetic mutations, eventu-
ally culminating in transformation to malignancy. In this review, we outline the many ways in which the HR- HPV oncoproteins 
manipulate the host cellular environment, focusing on how these activities can contribute to carcinogenesis.
INTRODUCTION
Papillomaviruses are small non- enveloped icosahedral 
viruses, possessing a circular double- stranded DNA (dsDNA) 
genome of approximately 8 kb in length [1]. To date, over 
400 isolates from a wide variety of fish, reptiles, birds and 
mammals have been reported in the Papillomaviridae family, 
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The study of human papillomaviruses (HPVs) has largely 
been driven by the severity of HPV- associated pathologies: 
whilst the HPVs that infect the cutaneous epithelium and 
typically result in benign wart or verruca formation, as 
well as the low- risk mucosal HPV types 6 and 11 associ-
ated with genital warts, have received some attention, the 
greatest focus has been on the high- risk HPVs (HR- HPVs) 
associated with the development of cancer [1, 4]. This link 
between HPV infection and cancer was first established over 
35 years ago when HPV16 DNA was found to be present in 
a large proportion of cervical cancer biopsies [5]. However, 
it is important to consider that the majority of HR- HPV 
infections will not progress to cancer; indeed 85 % of cases 
are subclinical transient infections [6]. There are currently 
15 recognized HR- HPV types: HPV16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, 68, 73, 82 [7]. Together, HR- HPVs are 
responsible for >99.7 % of cervical cancer cases, of which 
55 % are HPV16- positive and 15 % are HPV18- positive, 
along with a growing number or oropharyngeal cancers [8]. 
Cancer of the cervix is the fourth most common malignancy 
in women worldwide and the fourth leading cause of cancer- 
related deaths in women: in 2018, around 570 000 people 
were diagnosed with cervical cancer and over 300 000 deaths 
worldwide could be attributed to the disease [9]. Further-
more, HR- HPV infection is associated with cancers at a 
variety of other anogenital sites: around 50% of penile, 25 % 
of vulvar, 80 % of vaginal and close to 90 % of anal cancers 
are HPV- driven [10].
Although their expression is insufficient for progression to 
cancer, the main drivers of HPV- associated pathologies are the 
oncoproteins E5, E6 and E7 [11]. Together, they act to prolong 
the proliferation, and delay differentiation, of host keratino-
cytes to provide an environment suitable for viral replication. 
Many of the mechanisms by which this is achieved have been 
widely studied: HR- HPV E7 drives S- phase re- entry via 
binding to and inducing degradation of the retinoblastoma 
protein (pRb) and the related pocket proteins p107 and p130 
[12–16], whilst E6 concurrently targets p53 for proteasome- 
mediated degradation, inhibiting pro- apoptotic signalling in 
response to DNA damage caused by the abnormal S- phase 
entry [17, 18]. Additionally, E6 modulates a multitude of 
host signalling pathways, including the Hippo and JAK/
STAT pathways, to further promote proliferation and delay 
differentiation [19–21]. Whilst the role of HPV E5 is not well 
understood, it has been shown to drive cell proliferation by 
promoting epidermal growth factor receptor (EGFR)- induced 
signalling [22–24]. Importantly, if the expression of the viral 
oncoproteins becomes dysregulated, such as in the context 
of a persistent infection, cancer progression becomes more 
likely [11].
In this review, as well as outlining the basic biology of HPV 
and its life cycle, we aim to provide a comprehensive overview 
of the biological activities of each HPV oncoprotein in turn, 
with a particular focus on those of the HR- HPVs. We will 
illustrate the vital contributions each oncoprotein makes to 
the virus life cycle as well as addressing how these various 
functions may contribute towards carcinogenesis.
HUMAN PAPILLOMAVIRUSES
HPV genome organization
The HPV genome is organized into three functional sections: 
the early (E) region, the late (L) region, and an upstream regu-
latory region (URR) (Fig. 1a) [8]. Together, the early and late 
regions consist of nine ORFs, six in the early region (E1, E2, 
E1^E4, E5, E6, E7 and E8) and two in the late region (L1 
and L2), whilst the URR contains the origin of DNA repli-
cation (ori) as well as the transcription- factor binding sites 
required for the regulation of RNA- polymerase- II- dependent 
transcription. The three regions are separated by early and 
late polyadenylation sites (PAE and PAL, respectively). The 
HPV genome contains two major promoters: p97 in HPV16 
and 31 (p105 in HPV18) is responsible for expression of the 
early genes and lies upstream of the E6 ORF, and p670 in 
HPV16 (p811 in HPV18 and p742 in HPV31) is responsible 
for differentiation- dependent late gene expression and lies 
within the E7 ORF [25–27]. Although there are multiple 
minor promoters, their functions are poorly characterized 
[27]. Importantly, the HR- HPV E6 and E7 oncoproteins are 
encoded by a single bicistronic mRNA transcript with splicing 
allowing for the expression of each ORF [27].
HPV life cycle
The life cycle of HPV is intrinsically linked to the epithelial 
differentiation programme. For an infection to be established, 
virions must gain access to the basal lamina of the strati-
fied epithelium via microlesions or by entering cells at the 
squamo- columnar junction [1, 28]. Primary attachment of 
virions involves binding of the L1 capsid protein to heparin 
sulphate proteoglycans (HSPGs) on the basement membrane 
or on the surface of basal keratinocytes [29]. This induces 
conformational changes in the capsid structure, resulting in 
the exposure of the minor capsid protein L2 and binding to 
secondary receptors, the identity of which remains contro-
versial (see [30] for a review). This is followed by endocy-
tosis, which occurs via a clathrin-, caveolin-, cholesterol-, 
lipid raft- and dynamin- independent mechanism similar to 
micropinocytosis [31].
Capsid disassembly occurs in the late endosome, followed 
by trafficking of the viral genome, in complex with L1 and 
L2, towards the trans- Golgi network (TGN) [32–34]. This is 
mediated by direct interactions between L2 and components 
of the retrograde transport machinery such as the retromer 
complex, an ability conferred by the C- terminal cell- 
penetrating peptide possessed by L2 [35–37]. Onward nuclear 
trafficking is critically dependent upon the breakdown of the 
nuclear envelope during mitosis and requires binding of viral 
genomes to host mitotic chromosomes via L2 [38–40].
Following nuclear entry, the genome is thought to be rapidly 
amplified to around 50–100 copies per cell [8]. As HPV does 
not encode a polymerase, this is achieved via co- option of 
the host DNA replication machinery, a process mediated by 
the viral E1 and E2 proteins [41, 42]. Episomal copy number 
is then maintained in basal cells, where virus protein expres-
sion remains minimal due to E2- mediated repression of the 
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p97/p105 early promoter, aiding in avoidance of the immune 
response [43]. As the infected basal cell divides, one daughter 
cell remains in the basal layer and acts as an episomal reservoir 
whilst the other begins to migrate up through the epithelial 
layers. Here, expression of the viral oncoproteins E5, E6 and 
E7 delays terminal differentiation and prevents cell- cycle 
exit in order to provide a suitable environment for further 
genome amplification, which occurs in an extended G2- like 
environment [44, 45]. As the oncoproteins do not possess 
any intrinsic enzymatic activity, this must be achieved by 
interacting with and modulating the activity of host cellular 
factors.
The life cycle is completed in the uppermost layers of the 
epithelium after terminal differentiation has occurred and 
requires expression of the viral L1, L2 and E1^E4 proteins. 
Virion assembly occurs in the nucleus after importation of 
the L1 and L2 capsid proteins, followed by release of newly 
formed virus particles from the epithelial surface [46].
Dysregulation of the HPV life cycle during 
transformation
As is clear from the above section, carcinogenesis is not 
the default result of the HPV life cycle. Rather, it can be a 
consequence of a non- productive infection, and represents 
a ‘dead- end’ for the virus, as despite the synthesis of viral 
proteins, progeny virions are not produced. In most cases, 
HR- HPVs typically only cause a short- lived infection, which 
is cleared over a period of a few months; however in the event 
of a persistent infection, where the host immune system fails 
to detect and clear the virus efficiently, transformation may 
take place (Fig. 1b) [8].
The most important factor required for cancer progression 
is dysregulation of viral oncoprotein expression, prolonging 
their pro- proliferative effects upon the host cell [11]. 
Increased oncoprotein expression is often associated with 
integration of viral episomes into the host genome and can 
Fig. 1. Dysregulation of the HPV life cycle can contribute to carcinogenesis. (a) HPV16 genome organization, displaying the position of 
viral transcripts. The URR, and early and late promoters are also highlighted. (b) Schematic representation of the development of cervical 
cancer. Cancer typically progresses from cervical intraepithelial neoplasia (CIN). CIN is classified using a three- stage system based on 
the proportion of the epithelium displaying abnormalities. CIN1 represents a transient HPV infection, whilst CIN2 and 3 represent a 
persistent HPV infection with a risk of progression to cancer. Epithelial layers are outlined on the left. CIS, carcinoma in situ. (c) HPV16 
oncoprotein structure. Numbers refer to amino acid positions. TM, transmembrane domain; PBM, PDZ- binding motif; CR, conserved 
region; CKII, casein kinase II. Figure created using BioRENDER.com.
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confer a selective growth advantage to cells [47, 48]. Indeed, 
the majority of HPV16- associated cervical cancer cases and 
almost all HPV18- associated cases contain an integrated 
genome, as do 70 % of HPV- positive (HPV+) head and neck 
squamous cell carcinoma (HNSCC) cases [49, 50]. Frequently, 
oncoprotein overexpression is due to disruption of the E2 
ORF during integration, preventing E2- mediated repression 
of E6 and E7 expression [43, 48]. This can also be achieved 
through methylation of E2 binding sites within the viral URR 
[51]. Further, integration often results in hybrid virus- host 
transcripts, which are more stable than viral transcripts, thus 
potentially enhancing oncoprotein expression [52].
Significantly, given that the majority of HR- HPV infected 
cells do not progress to cancer, oncoprotein expression is 
necessary yet not sufficient for transformation [6]. It follows, 
therefore, that other genetic insults to host oncogenes and 
tumour suppressors are also required for progression to 
occur [49, 50]. Despite this, the cellular environment created 
by the activities of the HR- HPV oncoproteins discussed in 
the following sections of this review – that of rapid cell- cycle 
progression, abrogated cell- cycle checkpoints and genomic 
instability – is highly conducive to the acquisition of such 
host genetic aberrations.
THE E5 ONCOPROTEIN
The E5 protein is a poorly understood viral protein of between 
8 and 9.5 kDa expressed by a subset of HPV types, including 
the high- risk HPV16, 18 and 31 [53]. E5 is a membrane 
integrated, highly hydrophobic protein and HPV16 and 18 
E5 proteins contain three putative α-helical structures that 
function as transmembrane domains (TMDs) (Fig.  1c). 
The lack of antibody reagents for HPV E5 has hampered 
investigations into its biological functions during infection 
[53]; however, overexpression studies have elucidated some 
important aspects of E5 biology. HPV E5 primarily localizes 
to the endoplasmic reticulum and the Golgi apparatus, with a 
small proportion also observed at the perinuclear region and 
plasma membrane [54]. Furthermore, HPV16 E5 has been 
shown to oligomerize both in vitro and in cells [55]; however, 
this has not been observed in HPV- infected cells due to the 
lack of suitable reagents discussed above.
As an early gene, E5 plays an important role during the 
productive viral life cycle. Using HPV genomes lacking a 
functional E5 ORF, studies indicate that HPV16, HPV18 
and HPV31 E5 proteins have no apparent role in regulating 
viral genome maintenance or the proliferative ability of undif-
ferentiated keratinocytes [56–58]. In contrast, E5 has a clear 
role in the differentiation- dependent stages of the HPV life 
cycle. Our group demonstrated that HPV18 E5 is required for 
unscheduled DNA synthesis in suprabasal cells, but not for 
genome amplification or the expression of late viral proteins 
[56]. Interestingly, defective expression of the late viral 
protein E1^E4 was reported for HPV31 E5 knock out (E5KO) 
genomes, yet no E1^E4 defect has been observed with the 
corresponding HPV16 and HPV18 E5KO genomes [56–58]. 
These data therefore suggest that E5 proteins from different 
HPV types may have distinct roles during the productive viral 
life cycle.
The major transforming proteins of HPV are E6 and E7; 
however, for bovine papillomavirus (BPV) type 1, the major 
transforming protein appears to be E5 [59]. One critical 
function of BPV1 E5 is activation of the platelet- derived 
growth factor receptor (PDGFR), resulting in downstream 
mitogenic signalling, enhanced DNA synthesis and trans-
formation [60, 61]. This occurs via direct binding of BPV1 
E5 to the PDGFRβ isoform [62]. In contrast, there is no 
evidence for BPV4 E5 activation of growth- factor receptors; 
rather it disrupts the expression and activity of key cell- cycle 
regulators such as cyclin A and p27KIP1 [63]. Significantly, 
HPV E5 also does not bind to or activate the PDGFR, and 
HPV E5 proteins alone were found to be weakly oncogenic 
in comparison to HPV E6 and E7 in transgenic mouse 
models where the oncoproteins were expressed under the 
control of the epithelial specific keratin-14 (K14) promoter 
[64]. Furthermore, the expression of E5 is not detected in 
all HPV+ tumours, suggesting its contribution to transfor-
mation may rather be in the modulation or enhancement of 
E6 and E7 functions [65–67]. Indeed, E5 was demonstrated 
to enhance the oncogenic abilities of HPV16 E7 in primary 
baby- rat kidney cells [66], whilst in K14 transgenic mouse 
models, tumour formation was greater in mice expressing 
HPV16 E5/E6 or E5/E7, when compared with E6 or E7 alone 
[67]. Interestingly, tumour formation in mice expressing E5 
alone was only observed after treatment with oestrogen, an 
important driver of cervical carcinogenesis, indicating that 
E5 may promote, rather than initiate, tumourigenesis [67].
These studies have prompted investigations into how HPV 
E5 contributes to oncogenesis (Fig. 2). Many studies have 
demonstrated that E5 binds to a range of host proteins, several 
of which have been shown to function in the dysregulation 
of critical biological pathways associated with cellular trans-
formation (Table 1).
Induction of cell proliferation
Early studies suggested that, similar to the BPV1 E5 protein, 
one of the primary oncogenic functions of HPV E5 is the 
modulation of growth- factor signalling [22, 23]. To this 
end, HPV E5 has been shown to bind the growth- factor 
receptor ErbB4, promoting cell proliferation [68]. However, 
E5- mediated EGFR activation has been the most extensively 
studied aspect of its biological functions [22–24]. Our group 
demonstrated that HPV18 E5- induced EGFR signalling 
is critical in maintaining unscheduled DNA synthesis and 
cell- cycle progression during keratinocyte differentiation, 
suggesting that this function of E5 may contribute to both the 
virus life cycle and E5- mediated tumourigenesis [56]. Inter-
estingly, E5 activation of the EGFR is essential for E5- induced 
hyperplasia and cellular transformation in vivo [69]. Further, 
recent studies have demonstrated that the activation of EGFR 
by E5 can also induce the expression of the growth- factor 
receptor c- Met, a potent oncogene [70].
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Several mechanisms for EGFR activation by HPV E5 have 
been proposed. Initially, the interaction of E5 with the 16K 
subunit of the vacuolar H+- ATPase (v- ATPase) was suggested 
to abrogate its role in the endosomal acidification process, 
resulting in reduced EGFR degradation after growth- factor 
stimulation [71]. However, subsequent studies have shown 
that this may not be the case [72, 73]. HPV16 E5 has also been 
shown to bind directly to the EGFR, but this is not thought 
to be critical for E5- mediated EGFR activation [74]. HPV E5 
can also disrupt the interaction between the EGFR and the E3 
ligase c- Cbl, reducing EGFR ubiquitination and degradation, 
thereby enhancing mitogenic signalling [75].
Our lab has demonstrated an additional mechanism of EGFR 
activation induced by HPV16 E5. As mentioned above, 
HPV16 E5 forms oligomers and detailed biochemical studies 
demonstrated that E5 can function as a virus- encoded 
ion channel, a so- called viroporin [76, 77]. Interestingly, 
well- characterized broadly acting inhibitors of other 
viroporins, such as rimantadine, also inhibit E5 viroporin 
activity resulting in reduced E5- mediated EGFR activation 
[78]. Furthermore, this function of E5 was also shown to 
be important for the expression of mediators of cell- cycle 
progression, suggesting that viroporin activity may play a 
role in malignant transformation [78]. Further studies are 
Fig. 2. Summary of HPV E5 activities which contribute towards host- cell transformation. The host proteins and pathways reported to be 
modulated by HPV E5 are displayed, as well as the functional impact these have on the host cell. STAT, signal transducer and activator 
of transcription; MHC, major histocompatibility complex; EGFR, epidermal growth factor receptor; KGFR, keratinocyte growth factor 
receptor; AP-1, activator protein 1; FADD, Fas- associated protein with death domain. Figure created using BioRENDER.com.
Table 1. Host proteins known to interact with HPV E5
Protein name HR- HPV LR- HPV Proposed function Reference
16K subunit of v- ATPase + + Endosomal acidification [54, 275]
A4 + ? Increased proliferation [95]
Bap31 + ? Increased proliferation [96]
Calnexin + ? Immune evasion [88]
Calpactin I + ? Induction of koilocytosis [276]
EGFR + ? Increased proliferation [74]
ErbB4 + ? Increased proliferation [68]
EVER1 + ? Promotes AP-1 activation [277]
EVER2 + ? Promotes AP-1 activation [277]
HLA- I heavy chain + ? Immune evasion [94]
Karyopherin β3 + ? Unknown [278]
YIPF4 + + Unknown [279]
ZnT-1 + ? Promotes AP-1 activation [277]
+, interaction confirmed; ?, binding ability not analysed.
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required to identify the exact mechanism of EGFR activation 
by HPV E5.
As well as enhancing EGFR signalling, HPV16 E5 also 
downregulates expression of the anti- proliferative keratino-
cyte growth- factor receptor (KGFR) [56, 79]. Interestingly, 
E5- mediated downregulation of KGFR, also known as 
FGFR2b, is associated with an upregulation of its splice- 
isoform FGFR2c [80]. This isoform is highly expressed in 
mesenchymal- like cells and the induction of FGFR2c by 
HPV16 E5 promotes epithelial- mesenchymal transition 
(EMT), an important event in the progression to malignant 
transformation [80].
In addition to the modulation of growth- factor receptor 
signalling, HPV E5 can also promote cell proliferation by 
other mechanisms. Early studies demonstrated that HPV11 
and HPV16 E5 can induce expression of the proto- oncogene 
c- Jun, a key driver of cell proliferation [81]. Furthermore, 
whilst HPV16 E5 promoted mitogen- activated protein kinase 
(MAPK) signalling in response to EGF in the mouse 3T3 
fibroblast cell line, it also induced EGF- independent activa-
tion of MAPK via protein kinase C (PKC) signalling [82]. 
HPV E5 can also directly regulate cell- cycle progression via 
the inhibition of p21WAF1/CIP1 and p27KIP1 [83, 84].
Inhibition of apoptosis
An important hallmark of cancer cells is the ability to avoid 
apoptosis, particularly in response to death ligands. As a virus, 
HPV induces stress upon infected cells and the abrogation of 
cell- cycle checkpoints during infection promotes apoptosis. 
HPV has therefore evolved efficient mechanisms to prevent 
cell death. HPV16 E5 contributes towards this by promoting 
the proteasomal degradation of the pro- apoptotic Bcl-2 family 
member BAX upon reactive oxygen species (ROS)- induced 
apoptosis [85]. Furthermore, HPV16 E5 can prevent FasL- 
and TNF- related apoptosis- inducing ligand (TRAIL)- induced 
apoptosis by downregulating expression of the Fas receptor 
and inhibiting recruitment of Fas- associated protein with 
death domain (FADD) to form the death- induced signalling 
complex (DISC) [86]. HPV16 E5 can also inhibit the apop-
totic response to ultraviolet (UV)- B radiation; this requires 
E5- dependent activation of EGFR and downstream signalling 
through phosphatidylinositol 3- kinase (PI3K) and extracel-
lular signal- regulated kinase 1/2 (ERK1/2) [87].
E5-mediated immune evasion
E5 has also been shown to modulate the immune response 
to infection by interfering with the expression or trafficking 
of several critical immune receptors, including Major 
Histocompatibility Complex (MHC) class I, MHC class II 
and CD1d [88–92]. The cell- mediated arm of the adaptive 
immune response, which plays an essential role in the detec-
tion of virus- infected cells, functions by recognizing foreign 
protein epitopes on the surface of an infected cell in complex 
with MHC class I. E5 proteins from several HPV types (2a, 
16 and 83) have been shown to specifically downregulate 
HLA- A and HLA- B, abrogating their cell- surface expression 
and inhibiting T- cell recognition of HPV- infected cells 
[89, 90]. HPV16 E5 can bind directly to MHC class I via its 
first TMD, which may act to retain MHC class I within the 
Golgi apparatus, preventing its onward trafficking to the cell 
surface [93, 94]. Other mechanisms, such as the formation 
of a ternary complex with MHC class I and the chaperone 
calnexin, and/or a quaternary complex between HPV E5, 
MHC class I, Bap31 and A4, have also been speculated as 
possible explanations for the retention of MHC class I in 
the Golgi [88, 95, 96]. HPV E5 can additionally impede cell- 
surface expression of MHC class II and CD1d, suggesting 
that HPV E5 promotes subversion of the immune system via 
multiple mechanisms [91, 92].
The E5 oncoprotein is also capable of dysregulating interferon 
(IFN) signalling. HPV16 E5 can suppress the expression of 
STAT1, thus preventing downstream IFN- stimulated gene 
(ISG) transcription [97]. Furthermore, E5 silences expres-
sion of IFNκ, a key keratinocyte- specific IFN involved in 
antiviral immunity; although the exact mechanism for this 
remains to be determined, silencing results in abrogated ISG 
expression [97]. Interestingly, the effects on IFNκ expression 
were found to be, at least in part, dependent upon E5- induced 
EGFR signalling.
Recent data has suggested a potential role for E5 viroporin 
activity in the modulation of the host immune response. In a 
mouse model of HNSCC, HPV16 E5 expression resulted in a 
downregulation of MHC class I and this provided resistance 
to anti- programmed death- ligand 1 (anti- PD- L1) immu-
notherapy [98]. However, co- treatment with the viroporin 
inhibitor rimantadine sensitized tumours to anti- PD- L1 treat-
ment, suggesting that E5 viroporin activity is responsible for 
the resistance to these therapies and could hence be therapeu-
tically targeted using the currently available inhibitors [98].
THE E6 ONCOPROTEIN
E6 was first suspected to be an oncoprotein after analysis 
of cervical tumours and cervical cancer- derived cell lines 
revealed that the E6 ORF was retained during viral- genome 
integration and was highly expressed [99]. Follow- up 
experiments in human mammary epithelial and rat 
primary kidney cells confirmed that E6 possessed intrinsic 
transforming activities [100, 101]. Despite sharing some 
activities with their high- risk counterparts, low- risk E6 
proteins are unable to induce transformation in primary 
cells [102]. Interestingly, studies have demonstrated that E6 
and E7 likely cooperate in inducing tumour formation: E7 
drives early carcinogenesis whilst E6 accelerates progres-
sion towards malignancy [103]. In support of this, both the 
E6 and E7 ORFs were found to be required in the context 
of the full viral genome for the immortalization of primary 
human keratinocytes [104].
E6 proteins are approximately 150 amino acids long and 
contain two zinc- binding motifs formed by two pairs of 
CXXC sequences, which are essential for the activities of E6 
(Fig. 1c) [105]. Solving of the E6 structure by NMR revealed 
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that the protein has two zinc- finger domains termed E6N 
and E6C, each formed of a three- stranded β-sheet and two 
short helices, connected by a short linker helix [106, 107]. 
Further, high- risk E6 proteins contain a C- terminal PDZ 
(PSD-95/DLG/ZO-1) binding motif (PBM) formed of an 
X- S/T- X- V/L sequence (Fig. 1c) [108]. E6 is able to target 
a multitude of host cellular factors and perturb host signal-
ling pathways despite a lack of intrinsic enzymatic activity; 
these are summarized in Fig. 3, Table 2.
Blockade of pro-apoptotic signalling
The best- studied function of HR- HPV E6 is the degradation 
of the p53 tumour suppressor protein in order to disrupt 
pro- apoptotic signalling [109]. p53 is a sequence- specific 
DNA binding protein that serves as an effector of DNA 
damage and is mutated or inactivated in over half of all 
human cancers [110]. It is capable of inducing cell- cycle 
arrest, cellular senescence and apoptosis through transcrip-
tional regulation in response to a diverse range of stresses, 
and is itself under exquisite control by a number of mecha-
nisms, primarily by the E3 ubiquitin ligase mouse double 
minute 2 homologue (MDM2). Under normal cellular 
conditions, p53 undergoes rapid turnover due to binding of 
MDM2 and subsequent ubiquitination- dependent protea-
somal degradation. Cellular stress- induced phosphoryla-
tion of p53 precludes binding of MDM2, thus permitting 
transcriptional activation of target genes [110]. HR- HPV 
E6 can interact with the host E6- associated protein (E6- 
AP), a HECT domain- containing E3 ubiquitin ligase, by 
binding to its conserved LXXLL motif [17]. This allows the 
formation of a ternary complex with p53, which leads to its 
proteasomal degradation, thereby inhibiting p53- mediated 
apoptosis [18].
Importantly, E6- induced degradation does not totally deplete 
the host cell of p53, and low- risk E6 does not demonstrate an 
ability to degrade p53. HPV E6 proteins have therefore evolved 
additional degradation- independent mechanisms of inhib-
iting p53 signalling. E6 can prevent the acetylation of p53 by 
the related acetyltransferases p300 and CBP (CREB- binding 
protein) via the formation of a p53- E6- p300/CBP complex 
[111, 112]. E6 also inhibits the function of ADA3, which 
similarly promotes p53 acetylation and thus stabilization; 
although in contrast to p300/CBP, this is achieved via degra-
dation [113]. Direct binding of both high- risk and low- risk 
E6 proteins to the C- terminus of p53 has also been reported, 
as well as sequestration of p53 in the cytoplasm; these act to 
prevent p53 from interacting with DNA [105, 114]. Whilst the 
primary aim of these activities is to abrogate pro- apoptotic 
signalling in response to HPV E7- induced hyperproliferation, 
in the context of a persistent infection the prolonged loss of 
p53 function allows the accumulation of genetic mutations 
and thus contributes to cancer progression.
In addition to targeting p53, E6 targets other proteins 
involved in apoptosis. This includes binding to the host pro- 
apoptotic protein Bcl-2 homologous antagonist/killer (BAK) 
in order to suppress intrinsic apoptosis signalling. Similar to 
p53, E6 complexes with E6- AP to target BAK for degradation 
[115, 116]. Furthermore, E6 also dysregulates the extrinsic 
apoptosis pathway, which transmits extracellular apoptotic 
stimuli from the cell surface, through interactions with FADD 
Fig. 3. Summary of HPV E6 activities which contribute towards host- cell transformation. The host proteins and pathways reported to 
be modulated by HPV E6 are displayed, as well as the functional impact these have on the host cell. hTERT, human telomerase reverse 
transcriptase; PI3K, phosphatidylinositol 3- kinase; NHERF1, Na+/H+ exchange regulatory factor 1; STAT, signal transducer and activator 
of transcription; JAK, Janus kinase; YAP1, Yes- associated protein 1; STK4, serine/threonine- protein kinase 4; CASP8, caspase-8; TNFR1, 
tumour necrosis factor receptor 1; BAK, Bcl-2 homologous antagonist/killer; FADD, Fas- associated protein with death domain; HMTs, 
histone methyltransferases; DNMT1, DNA methyltransferase 1; SNX27, sorting nexin 27; IRF3, IFN regulatory factor 3; TRIM25, tripartite 
motif- containing protein 25. Figure created using BioRENDER.com.
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Table 2. Host proteins known to interact with HPV E6
Protein name HR- HPV LR- HPV Proposed function Reference
14-3-3ζ + - Stabilization of E6 [133]
ADA3 + - Inactivation of p53 [113]
AIF + + Increased survival [280]
BAK + + Increased survival [115. 116]
BARD1 + ? Defective DNA repair [281]
BCCIPβ + ? Promotes p53 ubiquitination [282]
BRCA1 + ? Defective DNA repair [283]
CARM1 + + Epigenetic reprogramming [175]
CASK + HPV40 only Unknown [132, 160]
Caspase-8 + - Increased survival [284]
CBP + low Inactivation of p53 [111, 112]
c- Myc + - Host- cell immortalization [285]
CYLD + ? Increased proliferation [286]
DLG1 + HPV40 only Increased proliferation [127, 128, 132]
DLG2 + - Unknown [160]
DLG4 + - Unknown [160, 287]
DVL2 + ? Increased proliferation [139]
E6- AP + + Degradation of p53 17, 18, 288]
FADD + ? Increased survival [117]
GIPC1 + ? Inhibition of TGFβ signalling [289]
GOPC + - Unknown [290]
GPS2 + + Unknown [291]
HERC2 + low Unknown [292, 293]
hTERT + ? Host- cell immortalization [294]
INADL + - Disruption of cell polarity [295, 296]
IRF3 + - Immune evasion [166]
KAT5 + + Activation of the HPV early promoter [297]
LIN7C + HPV40 only Unknown [132, 160]
MAGI1 + - Disruption of cell polarity [125]
MAGI2 + - Disruption of cell polarity [126]
MAGI3 + - Disruption of cell polarity [126]
MCM7 + low Chromosomal instability [298]
MGMT + ? Defective DNA repair [299]
MPDZ + - Increased proliferation [300]
MPP7 + HPV40 only Unknown [132, 160]
NFX1-123 + - Host- cell immortalization [301, 302]
NFX1-91 + - Host- cell immortalization [301, 302]
NHERF1 + + Wnt signalling activation [141, 154]
Continued
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and caspase-8, leading to their degradation [117, 118]. As 
these proteins are required to potentiate signalling from 
all death receptors, this allows the virus to inhibit extrinsic 
signalling from multiple receptors at once. HPV16 E6 has 
also been shown to directly bind the C- terminus of the trans-
membrane death receptor tumour necrosis factor receptor 1 
(TNFR1), further disrupting pro- apoptotic signalling [119].
Interaction with PDZ proteins
A property unique to the E6 oncoproteins of HR- HPVs is 
the presence of a C- terminal PBM [120]. This motif permits 
binding to a range of host proteins which possess PDZ 
domains, a protein–protein interaction motif of ~90 amino 
acids in length. An interaction with E6 has been confirmed 
for at least 19 PDZ proteins to date, although this repre-
sents only a fraction of the ~200 host PDZ proteins [108]. 
Despite this, the range of proteins possessing PDZ domains 
clearly allows E6 to regulate multiple aspects of the host- 
cell environment. Significantly, p53 degradation- defective 
HR- HPV E6 proteins are still capable of immortalizing cells, 
but those defective in binding PDZ partners are unable to 
induce epithelial hyperplasia, underlining the importance 
of modulating the activity of host PDZ proteins [121, 122]. 
Interestingly, several of the PDZ proteins confirmed to bind 
HPV E6, including SCRIB, discs large homologue 1 (DLG1), 
Na+/H+ exchange regulatory factor 1 (NHERF1) and the 
MAGI family of proteins, are regulators of cell polarity and 
cell–cell contacts [123–128]. The interaction with E6 results 
in the proteasomal degradation and/or mislocalization of 
the PDZ proteins, hence disrupting cell polarity, a common 
characteristic of malignant cells. E6 also targets sorting nexin 
27 (SNX27), utilizing the PDZ domain to dysregulate traf-
ficking of proteins such as glucose transporter 1 (GLUT1), 
essential for glucose uptake, thus disrupting cellular homeo-
stasis and proliferation [129]. Furthermore, our lab recently 
demonstrated that HR- HPV E6 proteins promote host cell 
proliferation and survival in a PBM- dependent manner via 
the activation of c- Jun N- terminal kinase 1/2 (JNK1/2) [130]. 
Taken together, these observations have led to the hypoth-
esis that targeting of PDZ proteins contributes significantly 
to HPV- induced transformation [131]. Indeed, the number 
of PDZ proteins bound by E6 correlates strikingly with the 
potential for oncogenicity: although binding to DLG1 is 
Protein name HR- HPV LR- HPV Proposed function Reference
p300 + low Inactivation of p53 [111, 112]
p53 + low Inhibition of apoptosis [17, 109, 114, 303, 304]
PML + + Inhibition of PML- induced senescence [305]
PRMT1 + + Epigenetic reprogramming [175]
PTPN13 + - Increased proliferation [306, 307]
PTPN3 + - Increased proliferation [160, 308]
RCN2 + - Unknown [309]
SCRIB + - Disruption of cell polarity; increased E6 expression [124, 132, 160, 310]
SET7 + + Epigenetic reprogramming [175]
SIPA1L1 + - Increased Rap1 GTPase activity [311, 312]
SNTB2 + - Unknown [[132]
TAX1BP3 + - Increased cell motility [313]
TNFR1 + ? Increased survival [119]
TRIM25 + + Immune evasion [168]
TSC2 HPV16 only - Increased mTORC1 signalling [155]
TYK2 + low Immune evasion [167]
USP15 + + Immune evasion [168, 220]
XRCC1 + - Defective DNA repair [314]
ZO-2 + - Increased cell migration [132]
Zyxin - HPV6 only Unknown [315]
+, interaction confirmed; -, no interaction recorded; low, limited binding detected; ?, binding ability not analysed.
Table 2. Continued
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shared by all HR- HPV E6 proteins, only those of HPV16 and 
18 are capable of binding SCRIB [132]. Binding of E6 to PDZ 
proteins can be abrogated by phosphorylation of a threonine 
residue within the PBM of E6 by AKT in the case of HPV16, 
or, for HPV18, by PKA [133].
Host-cell immortalization
E6 can promote oncogenesis through host- cell immor-
talization due to activation of the telomerase complex [134]. 
Increased telomerase activity and the subsequent lengthening 
of telomeres permits indefinite proliferation by circumventing 
the onset of senescence associated with excessive telomere 
shortening. Expression of HR- HPV E6 is necessary and suffi-
cient for telomerase activation: this is achieved via upregu-
lated expression of the catalytic subunit of telomerase, human 
telomerase reverse transcriptase (hTERT) [135, 136]. Signifi-
cantly, low- risk E6 proteins do not activate telomerase [137]. 
The mechanisms by which E6 promotes hTERT expression are 
complex and multi- layered (see [134] for a review): it hijacks 
several host factors, including specificity protein 1 (Sp1) and 
c- Myc to activate transcription, whilst also modulating the 
transcriptional repressors upstream stimulating factor 1 and 
2 (USF1 and USF2).
Dysregulation of host signalling networks
E6 achieves many of its oncogenic functions by dysregulating 
a multitude of host signalling pathways (Fig. 4). Collectively, 
this acts to drive proliferation of host cells, typically by modu-
lating the expression of downstream target genes associated 
with cell growth and survival. The pathways reported to be 
hijacked by E6 are outlined in turn in this section.
Wnt signalling pathway
The Wnt pathway is a highly conserved signalling axis impli-
cated in the regulation of development, but is also commonly 
dysregulated in cancer [138]. The main effector of canonical 
Wnt signalling is β-catenin which, in the absence of Wnt 
ligands, is rapidly phosphorylated by glycogen synthase 
kinase 3 beta (GSK3β), targeting it for ubiquitin- mediated 
degradation. Conversely, binding of a Wnt ligand to its 
cognate receptor leads to the stabilization and nuclear accu-
mulation of β-catenin and the transcription of genes associ-
ated with proliferation [138]. HPV16 E6 can bind directly to 
Dishevelled 2 (DVL2), a protein which impedes formation of 
the β-catenin degradation complex; this promotes β-catenin 
nuclear accumulation [139]. Additionally, evidence indicates 
that the E6/E6- AP complex can further stabilize β-catenin 
[140]; subsequent studies indicate this is likely associated with 
the ability of E6/E6- AP to interact with and induce the protea-
somal degradation of NHERF1, a negative regulator of canon-
ical Wnt signalling [141]. E6 is also reported to upregulate 
forkhead box protein M1 (FOXM1) expression, a β-catenin 
binding partner, which promotes its nuclear localization, via 
a myeloid zinc finger 1 (MZF1)/NK2 homeobox 1 (NKX2-1) 
signalling axis [142]. Further, cells in which expression of 
E6 and E7 is repressed display enhanced seven in absentia 
homologue 1 (SIAH1) expression, a protein implicated in 
β-catenin degradation, suggesting the oncoproteins may, to 
some degree, cooperate in dysregulating the Wnt pathway 
[143]. Unconstrained activation of the Wnt pathway leads 
to uncontrolled promotion of biological processes such as 
proliferation, differentiation and tumourigenesis.
Notch signalling pathway
The Notch pathway is a highly conserved signalling pathway 
essential for the regulation of proliferation, cell fate and 
differentiation [144]. The pathway is activated upon Notch 
ligand- receptor binding at the surface of adjacent cells, which 
induces a cascade of cleavage events to release the Notch intra-
cellular domain (NICD) from the membrane- bound receptor. 
NICD translocates to the nucleus to stimulate transcription 
of target genes in concert with the coactivator Mastermind- 
like protein 1 (MAML1). Aberrant activation of Notch has 
been reported in a wide variety of cancers, and intriguingly 
Fig. 4. HPV E6 modulation of host signalling pathways. Summary of the mechanisms by which HR- HPV E6 dysregulates the host Hippo, 
PI3K/AKT, Wnt/β-catenin and JAK/STAT signalling pathways. See text for details. Figure created using BioRENDER.com.
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both tumour suppressive and oncogenic roles for the pathway 
have been proposed, but the role of Notch signalling during 
HR- HPV infection and cervical cancer is less clear [145]. The 
Notch1 receptor has been observed to be transcriptionally 
upregulated in HPV16 E6- containing keratinocytes and 
also to increase with cervical cancer progression [146, 147]. 
Additionally, expression of both Notch receptors and ligands 
is upregulated in a significant proportion of HNSCC cases 
[148]. Conversely, a different study identified specific down-
regulation of the Notch1 receptor in HPV+ cervical cancer 
cell lines and invasive cervical carcinoma biopsies, and 
showed that reintroduction of NCID abrogated HPV onco-
protein expression [149]. Clearly, therefore, much remains 
to be understood regarding the role of Notch signalling in 
HPV- driven carcinogenesis.
PI3K/AKT/mTOR signalling pathway
The PI3K/AKT/mTOR signalling pathway is a key regulator 
of proliferation, metabolism and motility, and one of the most 
frequently dysregulated pathways in human cancers [150]. 
Given this essential role in the regulation of proliferation, 
it is unsurprising that HPV E6 dysregulates the pathway at 
multiple points. A key stage in this signalling axis involves 
the activation of class I PI3Ks by receptor tyrosine kinases 
(RTKs), allowing the phosphorylation of phosphatidylinositol 
4,5- bisphosphate (PIP2) to generate phosphatidylinositol 
3,4,5- trisphosphate (PIP3), a short- lived second messenger. 
This can be reversed, and the pathway thereby inactivated, 
through the phosphatase and tensin homolog (PTEN), a lipid 
phosphatase and bona fide tumour suppressor. Early reports 
demonstrated that HPV18 E6 expression was sufficient to 
induce increased PI3K and AKT phosphorylation [151]. 
This was hypothesized to be, at least in part, associated with 
the ability of HPV E6 to bind and degrade the PDZ domain- 
containing protein DLG1, a binding partner of PTEN, which 
promotes its stabilization [151, 152]. Furthermore, NHERF1, 
in addition to its role as a negative regulator of the Wnt 
pathway, can also inhibit PI3K signalling by promoting the 
recruitment of PTEN [153]. Therefore, E6- induced degrada-
tion of NHERF1 also contributes to uncontrolled PI3K/AKT 
signalling [154].
One of the many downstream targets of AKT is the mamma-
lian target of rapamycin complex 1 (mTORC1). mTORC1 
kinase activity is indirectly inhibited via the tuberous sclerosis 
complexes 1/2 (TSC1/2), which in turn are negatively regu-
lated by AKT phosphorylation [150]. It was initially thought 
mTORC1 could be activated by HPV16 E6- induced degra-
dation of TSC2 in an E6- AP- dependent manner [155, 156]. 
However, subsequent studies cast doubt upon these findings 
as no evidence for TSC2 degradation was apparent; rather 
mTORC1 activation was concluded to be achieved in an 
AKT- dependent manner [157]. Later, hyperactivity of a range 
of RTKs, including the EGFR, the insulin receptor (INSR) 
and the insulin- like growth factor receptor (IGF1R), was 
confirmed to contribute towards PI3K/AKT/mTOR pathway 
activation in HPV16 E6- expressing foreskin keratinocytes 
[158].
Hippo signalling pathway
The Hippo signalling pathway is a key pathway in organ 
homeostasis and is dysregulated in many types of cancer 
[159]. Activation of the canonical Hippo pathway results in 
the induction of a kinase cascade, ultimately leading to the 
phosphorylation of the downstream transcriptional regulators 
Yes- associated protein 1 (YAP1) and transcriptional coacti-
vator with PDZ- binding motif (TAZ). This promotes binding 
of 14-3-3 proteins to YAP1/TAZ and hence their cytoplasmic 
retention, ultimately resulting in proteasomal degradation. 
However, when the Hippo pathway is inactive, YAP1/TAZ 
localize to the nucleus and interact with the TEA domain 
(TEAD) family of transcription factors, leading to transcrip-
tion of genes involved in cell proliferation and survival.
HR- HPV is capable of dysregulating the Hippo signalling 
pathway at several stages. E6 has been shown to upregulate 
YAP1 protein levels by shielding it from proteasomal degra-
dation in a manner dependent on its PBM, resulting in the 
nuclear accumulation of YAP1 in both cervical tumours 
and HPV- containing keratinocytes [19, 160]. Indeed, YAP1 
overexpression alone is sufficient to induce cervical dysplasia 
[161]. Additionally, our studies have demonstrated that 
expression of the serine/threonine- protein kinase 4 (STK4), 
a key upstream negative regulator of YAP1/TAZ activity, is 
significantly downregulated in HPV+ cervical cancer [162]. 
Together, these activities lead to uncontrolled oncogenic 
YAP1 activity, contributing to the increased proliferation and 
survival necessary for tumourigenesis.
JAK/STAT signalling pathway
The Janus kinase/signal transducer and activator of transcrip-
tion (JAK/STAT) pathway is a key signalling axis associated 
with the regulation of embryonic development, stem- cell 
maintenance and the inflammatory response. Further, dysreg-
ulation of JAK/STAT signalling has also been shown to 
promote cancer progression, immune evasion and metastasis 
[163]. Pathway activation occurs upon binding of cytokines, 
interleukins and growth factors to a number of transmem-
brane receptors. This in turn results in activation of JAKs, 
followed by the recruitment, phosphorylation and activation 
of STAT proteins. Subsequently, STAT dimers translocate to 
the nucleus and bind to specific promoter sequences, leading 
to the transcription of target genes.
STAT3 drives proliferation in stratified epithelia and is essen-
tial for the maintenance of stemness. Studies in our lab have 
demonstrated that STAT3 phosphorylation is increased in 
HPV- containing keratinocytes in an E6- dependent manner 
and that this is required for episome maintenance in undif-
ferentiated cells as well as the continued proliferation of 
suprabasal cells [20]. A number of studies have confirmed 
that STAT3 phosphorylation is also increased in cervical 
cancer [164]; this is achieved through increased NFκB 
signalling and autocrine/paracrine activation of STAT3 by 
the pro- inflammatory cytokine interleukin-6 (IL-6) [21]. 
Importantly, we have shown that STAT3 activity, as well as 
that of the upstream kinase JAK2, is essential for proliferation 
and survival of cervical cancer cells [21, 165].
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E6-mediated immune evasion
Evidence also suggests that E6 is capable of modulating 
the immune response to infection. HR- HPV E6 proteins 
interact with a component of the innate immune response: 
IFN regulatory factor 3 (IRF3) [166]. This interaction is 
thought to prevent the transactivation of IFNβ expression 
and hence the induction of ISGs. Furthermore, HPV18 E6 
has been demonstrated to directly interact with and impair 
activation of the non- receptor tyrosine kinase 2 (TYK2), 
thus inhibiting the induction of JAK/STAT signalling [167]. 
Disruption of the immune response can also be achieved via 
dysregulation of the RIG- I pathway: E6 proteins from several 
high- risk types bind to TRIM25 and USP15, two key activa-
tors of RIG- I, promoting the ubiquitination and degradation 
of TRIM25 and ultimately inhibiting the activation of RIG- I 
signalling [168]. Furthermore, E6 inhibits transcription of 
the keratinocyte- specific IFNκ, in addition to E5- induced 
methylation of its promoter, to prevent activation of antiviral 
ISGs and pattern recognition receptors (PRRs) [97, 169].
Epigenetic reprogramming of host cells
Significant alterations to host chromatin modification 
patterns, including DNA methylation and histone acetylation/
methylation, are observed during HPV infection. Aberrant 
DNA methylation at promoter regions is an important way in 
which loss of tumour suppressor gene expression can occur 
during carcinogenesis and has been reported in cervical 
cancer [170]. One of the major mechanisms associated with 
this likely involves oncoprotein activation of DNMT1, the 
methyltransferase responsible for maintenance of DNA 
methylation levels. Indeed, HPV infection has profound 
effects upon the host methylome: 8000 and 10 000 genes were 
demonstrated to have altered DNA methylation levels, either 
increased or decreased, in primary keratinocytes harbouring 
episomal HPV16 and HPV18 genomes, respectively [171]. 
E6 indirectly increases DNMT1 expression through the 
degradation of p53 [172]. p53 negatively regulates DNMT1 
expression by binding in concert with Sp1 to the DNMT1 
promoter but in the absence of p53, Sp1 acts to enhance 
DNMT1 expression [173]. Whilst the full functional impact 
of E6- mediated modulation of the host methylome remains to 
be understood, it has been shown that E6 expression leads to 
hypermethylation and hence silencing of the death associated 
protein kinase 1 (DAPK1) promoter, a tumour suppressor that 
is a key mediator of IFNγ-induced, as well as apoptotic, cell 
death [174].
Additionally, E6 can affect host chromatin structure via the 
dysregulation of histone- modifying enzymes. Both high- risk 
and low- risk E6 proteins interact with the histone methyl-
transferases coactivator associated arginine methyltransferase 
1 (CARM1), protein arginine methyltransferase 1 (PRMT1) 
and SET7, resulting in inhibition of their enzymatic activity 
[175]. Together, this provides another mechanism by which 
HPV modulates p53 function: CARM1 and PRMT1 are 
required to activate transcription from p53- responsive 
promoters, whilst SET7 has an additional function in 
methylating, and hence stabilizing, p53 [175]. Importantly, 
however, loss of the activity of these methyltransferases is 
likely to have wider impacts upon cellular functions due to 
global changes in gene transcription, which remain to be 
elucidated.
Targeting of non-coding RNAs
Emerging evidence indicates that the HPV oncoproteins 
are also capable of targeting non- coding RNA (ncRNA) 
species, including microRNAs (miRNAs), long non- coding 
RNAs (lncRNAs) and circular RNAs (circRNAs), in order 
to manipulate the host- cell environment. All three of these 
ncRNA types have been documented to be dysregulated in 
HPV infection and cervical cancer, with effects that promote 
proliferation and contribute to delayed differentiation (see 
[176] for a review).
miRNAs are short, ~22 nucleotide non- coding RNA species 
expressed in nearly all eukaryotes [177]. miRNAs typically 
downregulate gene expression by binding to the 3′UTR of 
target transcripts, promoting their cleavage. Despite the 
numerous studies evaluating the expression of miRNAs in 
cervical neoplasia and cervical cancer tissue biopsies, the 
mechanisms behind the observed changes in expression 
are often poorly understood. However, HR- HPV E6 has 
been demonstrated to directly regulate the expression of a 
collection of miRNAs. Among these, downregulation of 
the tumour suppressive miRNAs miR- 34a and miR-218 has 
been reported in both HPV+ cell lines and HPV+ cervical 
lesions [178, 179]. Conversely, E6- induced enhancement of 
miR- 20a and miR- 20b expression likely contributes towards 
increased proliferation and invasion of cervical cancer cells 
[180, 181]. Furthermore, studies in our group indicate that 
oncoprotein- induced expression of the oncogenic miR- 18a 
contributes towards the dysregulation of Hippo signalling 
discussed previously by silencing STK4 expression [162]. 
Importantly, we demonstrated that reintroduction of STK4, 
or transfection of an antagomir to inhibit miR- 18a, led to a 
reduction in proliferation [162].
LncRNAs are RNA molecules greater than 200 nucleotides 
long and possess many of the same structural features of 
mRNAs but lack a recognizable ORF [182]. They can localize 
to both the nuclear and cytoplasmic compartments of the 
cell and have many modes of action, including inhibition 
of miRNAs via sponging, epigenetic regulation of gene 
expression and stabilization of mRNA transcripts [182]. 
LncRNAs have been documented to promote cancer devel-
opment through their regulation of proliferation, apoptosis 
and invasion, and could also serve as cancer biomarkers. 
Cervical cancer is no exception to this, and a number of 
lncRNAs have been demonstrated to be dysregulated during 
progression [176]. For example, expression of the cervical 
carcinoma expressed PCNA regulatory (CCEPR) lncRNA 
is markedly increased in cervical cancer, and expression 
directly correlates with tumour size and poor prognosis [183]. 
Expression of CCEPR was later shown to be driven by HPV16 
E6 in a p53 degradation- independent manner [184]. The 
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expression of other lncRNAs, including FAM83H antisense 
RNA 1 (FAM83H- AS1) and H19, was also demonstrated to 
be increased in HPV16 E6- expressing primary keratinocytes, 
although precise mechanisms are yet to be elucidated [185].
THE E7 ONCOPROTEIN
The E7 protein is considered to be the major transforming 
protein of HR- HPVs and its continued expression is essential 
for carcinogenesis [186, 187]. Underlining its importance, 
sequencing of viral genomes has revealed remarkable amino 
acid sequence conservation of the E7 protein in high- grade 
cervical neoplasia and cervical cancer specimens [188]. 
The protein is ~100 amino acids long and possesses two 
conserved regions (CR1 and CR2) at its N- terminus, which 
show significant similarity to other DNA virus oncoproteins, 
including adenovirus E1A and simian virus 40 (SV40) large 
tumour antigen (Fig. 1c) [189]. Within CR2 lies the conserved 
LXCXE motif necessary and sufficient for binding to pRb, and 
a casein kinase II phosphorylation site [12, 190, 191]. The 
C- terminus of E7 is less well- conserved except for two CXXC 
zinc- binding motifs [186]. E7 possesses both nuclear localiza-
tion and nuclear export signals (NLS and NES, respectively), 
suggesting that it shuttles between the cytoplasm and nucleus 
and has functions in both compartments [192]. Much like E6, 
the E7 oncoprotein is multifunctional (Fig. 5), and is reported 
to interact with numerous host proteins (Table 3).
Targeting of the retinoblastoma protein (pRb) 
family of tumour suppressors
The best- characterized function of E7 is dysregulating the 
G1/S- phase transition in order to promote increased prolif-
eration by disrupting E2F transcription factor activity. The 
E2F transcription factors typically consist of an E2F subunit 
(E2F1-6) and a DP subunit (DP1-3), although two additional 
non- canonical family members, E2F7 and E2F8, have been 
reported (see [193] for a review). E2F transcription factors 
can be broadly divided into activators of transcription (E2F1, 
2, 3a and 3b), which preferentially bind pRb, and repressors 
(E2F4-8). Within a naïve cell, phosphorylation of pRb by 
CDK2, CDK4 or CDK6 during G1 phase induces dissociation 
of E2Fs, leading to expression of genes necessary for S- phase 
progression. However, during infection, dysregulation of E2F 
transcription factors is achieved primarily by binding of E7 
to pRb and the related pocket proteins p107 and p130 via 
the conserved LXCXE motif located within its CR2 domain 
[12–14]. Some evidence indicates that sequences within the 
C- terminus of E7 may also be required for pRb binding [194]. 
Binding of E7 disrupts pRb- E2F complexes, releasing E2Fs 
from repression and hence enabling the expression of E2F- 
dependent genes associated with cell- cycle progression such 
as cyclins A and E, contributing towards S- phase re- entry in 
differentiating suprabasal keratinocytes [11]. Concurrently, 
binding of HPV E7 to p107 and p130 leads to disruption of 
the dimerization partner, pRb- like, E2F and multi- vulval 
Fig. 5. Summary of HPV E7 activities which contribute towards host- cell transformation. The host proteins and pathways reported to be 
modulated by HPV E7 are displayed, as well as the functional impact these have on the host cell. PTPN14, protein tyrosine phosphatase 
non- receptor type 14; TGFβ, transforming growth factor beta; HDACs, histone deacetylases; SRC1, steroid receptor coactivator 1; DNMT1, 
DNA methyltransferase 1; KDM6A/B, lysine demethylase 6A/B; CDK2, cyclin- dependent kinase 2; pRb, retinoblastoma protein; DREAM, 
dimerization partner, pRb- like, E2F and multi- vulval class B; ATM, ataxia- telangiectasia mutated; ATR, ataxia- telangiectasia and Rad3- 
related; IRF, IFN regulatory factor; TLR9, Toll- like receptor 9; cGAS, cyclic GMP- AMP synthase; STING, stimulator of IFN genes; IL- 18BP, 
interleukin-18 binding protein. Figure created using BioRENDER.com.
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Table 3. Host proteins known to interact with HPV E7
Protein name HR- HPV LR- HPV Proposed function Reference
Actin (F- actin) + ? Cytoskeletal rearrangements [316]
AP-1 (c- Jun, JunB, JunD, c- Fos isoforms) + ? Increased transforming ability [317]
ATM + ? DDR activation [233]
B- Myb/MuvB complex + low Increased proliferation [318]
BRCA1 + ? Defective DNA repair [283]
BRG1 + - Increased proliferation [319]
Calpain + ? pRb destabilization [200]
Casein kinase II + + Increased transforming ability [190, 191]
CDK2 + + Increased proliferation [207, 320]
CENP- C + - Unknown [321]
CHD4 + ? Increased proliferation [250]
c- Myc + + Increased c- Myc activity [322]
Cullin 1 + ? Ubiquitin- mediated degradation of E7 [323]
Cullin 2 HPV16 only - pRb degradation [198, 199]
Cullin 3 + + Unknown [199]
Cyclin A + + Increased proliferation [14, 207]
Cyclin E + + Increased proliferation [207, 320]
DNMT1 + ? Altered host methylome [246]
DYRK1A + ? Phosphorylation and stabilization of E7 [324]
E2F1 + low Increased proliferation [203]
E2F6 + + Increased proliferation [206]
ENC1 HPV18/45 only - Unknown [199]
FHL2 + ? Impaired FHL2 coactivator function [325]
FOXM1 + ? Increased transforming ability [326]
Gelsolin + ? Cytoskeletal rearrangements [327]
GRP78 + ? Increased oncoprotein stability [328]
GSTP1 + ? Increased survival [329]
HDAC1 + ? Increased proliferation [250]
HDAC2 + ? Increased proliferation [250]
HIF-1α + + Promotes angiogenesis [330]
HTRA1 + ? Unknown [331]
IGFBP-3 + low Increased survival [332]
IKKα + ? Immune evasion [323]
IKKβ + ? Immune evasion [333]
IRF1 + + Immune evasion [226]
IRF9 + ? Immune evasion [225]
KCMF1 + + Unknown [199]
MAP4 HPV16 only low Deregulation of mitosis [334]
Miz-1 + + Inhibition of p21 expression [335]
Continued
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Protein name HR- HPV LR- HPV Proposed function Reference
NDKA + ? Unknown [336]
NDKB + ? Unknown [336]
NLRX1 HPV16 only ? Immune evasion [337]
NuMA1 + + Deregulation of mitosis [338]
Nup62 + ? Nuclear import of E7 [339]
Oct4 + ? Unknown [340]
p107 + low Increased proliferation [14, 202, 341]
p130 + low Increased proliferation [14, 202, 341]
p190RhoGAP + + Cytoskeletal rearrangements [342]
p21CIP1 + low Increased proliferation [210, 211]
P26s4 + ? Increased proteasome activity [343]
p27KIP1 + low Increased proliferation [209]
p300 + low Epigenetic reprogramming [255]
pCAF + + Epigenetic reprogramming [253, 254]
PKM2 + - Metabolic changes [344]
PML + + Inhibition of PML- induced senescence [345]
PP2A + + Increased PI3K/Akt signalling [346]
pRb + low Increased proliferation [12, 13, 202]
PTPN14 + + Increased proliferation; impaired differentiation [212–215]
PTPN21 + ? Unknown [215]
Ran + ? Nuclear import of E7 [347, 348]
Siva + ? Increased survival [349]
SMAD1 + + Increased proliferation [350]
SMAD2 + + Increased proliferation [217, 350]
SMAD3 + + Increased proliferation [217, 350]
SMAD4 + + Increased proliferation [217, 350]
SNW1 + low Inhibition of SNW1 coactivator function [351]
SRC1 + - Epigenetic reprogramming [256]
STING HPV18 only ? Immune evasion [219, 337]
TAF1C + ? Dysregulation of RNA polymerase I transcription [352]
TAP1 + ? Immune evasion [353]
TBP + ? Inhibition of TBP DNA binding [354]
TG2 + + Unknown [355]
UBR4 + + Resistance to anoikis; PTPN14 degradation [199, 212, 245]
ZER1 HPV16 only - pRb degradation [199]
α-glucosidase + ? Increased glycogen turnover [356]
γ-tubulin + ? Defective centrosome duplication [241]
+, interaction confirmed; -, no interaction recorded; low, limited binding detected; ?, binding ability not analysed.
Table 3. Continued
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class B (DREAM) repressor complex, permitting a further 
enhancement in the expression of proliferative genes [195]. 
E7- pocket protein binding and S- phase entry is significantly 
enhanced by casein kinase II phosphorylation of serine-32 
and -34 residues within the CR2 domain [196, 197].
Further, HR- HPV E7 proteins can target Rb family members 
for proteasomal degradation via a mechanism that requires 
binding to the cullin 2 ubiquitin ligase complex by E7 
[15, 16, 198, 199]. E7- induced degradation also requires 
cleavage of pRb by the protease calpain-1; this unmasks a 
C- terminal unstructured region of pRb, which acts as an 
efficient initiation region for degradation by the protea-
some [200, 201]. In contrast, low- risk E7 proteins have a 
significantly weaker affinity for the pocket proteins, which 
likely contributes to their lack of transforming activity [12]. 
Interestingly, only p130 degradation has been reported for the 
low- risk E7 proteins, suggesting that destabilization of this 
pocket protein is vital for the HPV life cycle yet dispensable 
for tumourigenesis [202].
Other mechanisms underlying dysregulation of the 
G1/S cell-cycle checkpoint
In addition to indirectly modulating E2F activity through 
targeting pRb, E7 also possesses other mechanisms of affecting 
E2F transcription factors. A direct interaction between E7 and 
E2F1 has been reported; this leads to a further increase in 
E2F- dependent gene expression [203]. A consequence of this 
is heightened expression of the repressive E2F6 transcription 
factor, which likely constitutes a feedback loop to prevent 
inappropriate expression of E2F1- dependent genes at other 
stages of the cell cycle [204]. E2F6 acts as a transcriptional 
repressor of E2F- responsive promoters by recruiting poly-
comb group (PcG) complexes and histone methyltransferases 
[205]. This negative feedback loop can be negated by binding 
of E7 to E2F6, leading to its inactivation [206].
E7 proteins are also able to dysregulate the G1/S- phase 
checkpoint in other ways. The activity of CDK2, a kinase 
crucial for S- phase entry and progression, is maintained via 
an interaction between its cognate cyclins (cyclin E and cyclin 
A) and E7 (Fig. 6) [207]. This is on top of already heightened 
cyclin A and E levels; their expression is regulated by E2Fs 
and is hence increased in E7- containing cells [208]. Further, 
the activities of the CDK inhibitors p21CIP1 and p27KIP1, which 
are implicated in mediating keratinocyte differentiation via 
inducing a G1 cell- cycle arrest, are suppressed by E7 binding 
(Fig. 6) [209–211]. Together these mechanisms act to ensure 
the efficient S- phase re- entry of differentiating suprabasal 
epithelial cells.
Impairment of differentiation
In addition to its roles in driving proliferation, emerging 
evidence indicates that E7 may also play a role in impairing 
cellular differentiation. A diverse range of E7 proteins possess 
the ability to bind the non- receptor protein tyrosine phos-
phatase PTPN14, with HR- HPV E7 proteins additionally 
able to target it for proteasomal degradation using the UBR4 
ubiquitin ligase [212, 213]. This loss of PTPN14 is critical 
in both delaying the epithelial differentiation programme 
and for cellular transformation, although evidence that this 
is achieved via modulation of Hippo pathway signalling 
remains controversial [214, 215]. Interestingly, mutational 
analyses indicate that this constitutes one of the as yet poorly 
defined pRb- independent functions of E7: regions in both 
CR1 and the C- terminus are necessary for formation of the 
E7/PTPN14/UBR4 complex.
Fig. 6. Dysregulation of cell- cycle checkpoints by HPV E7. The mechanisms employed by HPV to include cell- cycle progression are 
illustrated. HPV E7 binds to and induces the degradation of the retinoblastoma protein (pRb) in a cullin 2 (CUL2) ubiquitin ligase- 
dependent manner. This releases the E2F1 transcription factor from inhibitory complexes, permitting the expression of genes associated 
with S- phase progression. Degradation of the related pocket proteins p107 and p130 prevents inhibition of G1 progression by the DREAM 
complex. HPV E7 also binds directly to cyclins A and E, potentiating cyclin- dependent kinase 2 (CDK2) activity. Further, HPV E7 can 
suppress the activity of the CDK inhibitors p21 and p27, allowing increased cyclin/CDK phosphorylation of pRb and enhanced E2F1- 
dependent transcription. HPV E6 also indirectly contributes towards cell- cycle progression: E6- associated protein (E6- AP)- dependent 
degradation of p53 prevents induction of p21 expression. Figure created using BioRENDER.com.
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Manipulation of the TGFβ pathway by E7 may also contribute 
towards delaying epithelial differentiation. Expression of 
HPV16 E7 was shown to block TGFβ-mediated suppres-
sion of c- Myc expression [216]. Mechanistically, one report 
claimed that the negative effects of TGFβ signalling on cell 
proliferation are abrogated by binding of HPV16 E7 to 
SMAD2, SMAD3 and SMAD4, thus preventing the associa-
tion of SMADs with their DNA- binding elements [217].
E7-mediated immune evasion
Much like the other oncoproteins, E7 plays a role in immune 
evasion by HPV by targeting several stages of the cellular 
antiviral response. Indeed, recent evidence suggests that 
expression of both E6 and E7 is necessary to repress the 
innate immune response [218]. A key target for HPV are 
the host PRRs: direct binding of HPV18 E7 to STING, in a 
manner dependent on its LXCXE pRb- binding motif, results 
in inhibition of the cGAS- STING signalling axis, a major 
pathway involved in the recognition of exogenous DNA 
[219]. Signalling is further repressed in HPV+ cervical cancer 
cells via E7- induced upregulation of the H3K9- specific DNA 
methyltransferase SUV39H1, leading to the suppression of 
cGAS and STING expression [220]. The histone demethylases 
KDM5B and KDM5C also participate in STING silencing 
by promoting removal of the activatory histone marker 
H3K4me3 [221]. Indeed, expression of KDM5B and STING 
are negatively correlated in HPV+ cancers [221]. Additionally, 
HPV16 E7 is able to promote the epigenetic silencing of the 
dsDNA sensor Toll- like receptor 9 (TLR9) via recruitment 
of KDM5B and the histone deacetylase HDAC1 to the TLR9 
promoter [222]. Together, these measures act to prevent 
production of type I IFNs.
Immune signalling downstream of PRRs is also modulated 
by HPV. The transcription factor NFκB can be activated by 
numerous inflammatory stimuli and plays a major role in 
anti- viral immunity. Our group identified that E7 proteins 
from both high- risk and low- risk types prevented activa-
tion of NFκB signalling in primary keratinocytes, leading 
to reduced secretion of pro- inflammatory cytokines [223]. 
Further, we showed that E7 expression augments secretion 
of IL-18 binding protein (IL- 18BP), an anti- inflammatory 
cytokine, in response to IFNγ stimulation [224].
The IFN response is also suppressed via binding of E7 to IRF9, 
abrogating the expression of ISGs [225]. IRF1 is similarly 
thought to be targeted by high- risk E7 proteins: direct binding 
of HPV16 E7 to the C- terminus of IRF1 precludes binding to 
DNA and hence prevents expression of target genes such as 
IFNβ [226].
Furthermore, mouse models have demonstrated that HPV16 
E7 expression results in a locally immunosuppressive environ-
ment where cytotoxic T lymphocyte function is significantly 
suppressed [227]. Mechanistically, this could be associated 
with reduced expression of the chemokine CXCL14, observed 
in both cervical cancer and HPV+ HNSCC tissue, due to 
E7- dependent promoter hypermethylation. Importantly, 
reintroduction of CXCL14 results in increased immune cell 
infiltration and suppresses tumour growth [228]. HPV E7 
may also interfere with MHC class I surface expression, in 
addition to the role played by E5, in order to prevent NK 
cell- mediated killing [229].
Replication stress and genomic instability
Genomic instability is a hallmark of HPV+ cancers, but is also 
frequently observed in premalignant cervical lesions [230]. 
Aberrant activation of the pRb- E2F pathway by HPV E7 and 
the ensuing unscheduled proliferation is sufficient to induce 
replication stress and genomic instability due to inadequate 
nucleotide pools [231, 232]. In support of this, HPV has been 
demonstrated to activate both the ATM (ataxia- telangiectasia 
mutated) and ATR (ataxia- telangiectasia and Rad3- related) 
DNA damage response (DDR) pathways, which are induced in 
response to DNA double- strand breaks and replication stress 
respectively [233–235]. Significantly, inhibition of either of 
these DDR signalling pathways has an adverse effect on viral 
genome amplification, suggesting that the virus has evolved 
to not only tolerate replication stress and the DDR, but to 
require them for its life cycle [233, 234]. Mechanistically, 
ATM activation is thought to be accomplished via a non- 
canonical route involving STAT5 signalling, which is at least 
in part E7- driven, and the acetyltransferase Tip60 [236, 237]. 
STAT5 is also implicated in driving the ATR- DDR response: 
HPV31 E7- induced STAT5 phosphorylation drives transcrip-
tion of TopBP1, which subsequently binds and stimulates the 
kinase activity of ATR [234]. Importantly, the E1 helicase can 
similarly activate the DDR, and a recent study demonstrated 
that DDR activation occurs to the same extent in keratino-
cytes containing HPV16 genomes lacking functional E6 and 
E7 ORFs as with wild- type HPV16 genomes, leading to the 
hypothesis amongst some that viral replication itself may also 
play a key role in DDR activation [218].
Intriguingly, a recent study suggests that DNA repair factors 
may be recruited away from host DNA towards viral genomes 
[232]. Indeed, several ATM- DDR signalling components, 
including ATM, γH2AX, Chk2 and BRCA1, are localized to 
the sites of viral replication during an infection, perhaps to 
ensure high- fidelity genome replication [238]. This has led to 
the hypothesis that HPV episomes are shielded from the DNA 
damage ensuing from oncoprotein- induced replication stress, 
and that this may contribute to the DNA lesions and genetic 
instability in the host genome necessary for progression to 
cancer [232].
Other potential methods of inducing genomic instability 
have also been reported. Expression of HPV16 E7 can 
rapidly induce abnormal centrosome numbers in the 
host cell due to defective centrosome duplication, which 
in turn permits chromosome missegregation, aneuploidy 
and genomic instability [239, 240]. Additionally, an associa-
tion between E7 and γ-tubulin has been reported [241]. 
This purportedly delays the recruitment of γ-tubulin to 
centrosomes, further contributing to the subversion of 
centrosome duplication.
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Resistance to anoikis
Anoikis is a form of programmed cell death induced upon 
detachment from the extracellular matrix and resistance 
to anoikis (i.e. anchorage- independent growth) is a key 
hallmark of cancer cells [242]. Expression of BPV1 E7 was 
found to stimulate anchorage- independent cell growth and 
this correlated with its ability to bind UBR4 (also known as 
p600) [243, 244]. An interaction between UBR4 and HPV16 
E7 was also reported and indeed this ability to bind UBR4 
was later found to be conserved across many HPV types 
[199, 245]. Importantly, depletion of UBR4 in the presence of 
E7 inhibited anchorage- independent growth, suggesting this 
is likely a mechanism by which papillomaviruses dysregulate 
anoikis [243, 245]. More recently, the interaction between E7 
and UBR4 was found to be required for PTPN14 degradation 
and that this contributes towards delaying keratinocyte differ-
entiation, as discussed previously in this section [212–214]. 
However, PTPN14 knockout also reduced detachment- 
induced cell death, perhaps indicating that targeting of this 
pathway by HPV may concurrently impact upon differentia-
tion and anoikis [214].
Epigenetic reprogramming of host cells
In addition to the role played by E6 in dysregulating host 
epigenetic regulatory mechanisms, E7 can also induce 
significant alterations to cellular chromatin modification 
patterns. In some cases, the oncoproteins concurrently target 
the same host factor, such as the DNA methyltransferase 
DNMT1. Further to indirect activation of DNMT1 through 
E6- mediated p53 degradation, direct binding of HPV16 E7 
to DNMT1 is sufficient to promote its enzymatic activity 
[246]. Moreover, the expression of DNMT1 and DNMT3B is 
reportedly increased in keratinocytes harbouring episomal 
HPV genomes [171].
E7 can additionally induce changes to cellular histone modi-
fications. As discussed elsewhere in this review, modulating 
the expression and activity of histone- modifying enzymes 
can contribute to suppression of the host immune response 
[220–222]. In addition to this, a genome- wide reduction in 
levels of the repressive histone mark H3K27me3 has been 
reported in HPV16 E7- expressing keratinocytes due to 
transcriptional induction of the KDM6A and KDM6B lysine 
demethylases, whilst KDM6A expression is also significantly 
upregulated in HPV+ tumours [247, 248]. Cervical cancer 
cells have been demonstrated to be addicted to KDM6A: it 
is thought that loss of H3K27 trimethylation due to KDM6A 
activity promotes p21CIP1 expression, which is required to 
survive E7- induced replication stress [249] .
E7 also interacts with histone deacetylases (HDACs), which 
function by removing acetyl groups from histone lysine 
residues, thus inducing chromatin remodelling and tran-
scriptional repression [250]. Binding of E7 to HDACs was 
found to be essential for the HPV31 life cycle; this is likely 
associated with promoting S- phase progression in differen-
tiating keratinocytes by increasing levels of E2F2- dependent 
transcription [251, 252]. Similarly, E7 can also associate with 
the histone acetyltransferases (HATs) p300, pCAF and SRC1 
[253–256]. Whilst the biological relevance remains to be 
fully elucidated, it is clear that these interactions can result 
in reduced HAT activity.
Targeting of non-coding RNAs
Like E6, recent evidence indicates that HPV E7 can directly 
modulate the expression of multiple miRNAs, such as 
miR-203. The primary role of miR-203 is to promote epithelial 
differentiation by inducing cell- cycle exit, and as such levels 
of miR-203 increase in a differentiation- dependent manner 
[257]. Induction of the differentiation programme is achieved 
by downregulating expression of p63, a key driver of prolifera-
tion in epithelial tissue, which is commonly overexpressed 
in both HNSCC and cervical cancer [257, 258]. Suppression 
of miR-203 expression by E7 permits increased protein 
levels of ΔNp63, the major epithelial p63 isoform, and hence 
contributes to delaying epithelial differentiation [258]. Other 
miRNAs purportedly targeted by E7 include miR-16, miR34b, 
miR- 34c- 5p and miR-486–5 p, although the significance of 
these in relation to the HPV life cycle and cancer progression, 
as well as exact mechanisms, remain to be elucidated [259].
Co- regulation of miRNAs by E6 and E7 has also been 
reported: both oncoproteins contribute to the suppression 
of miR-424 in order to promote HPV genome amplification, 
whilst our data indicates that upregulation of the oncogenic 
miR- 18a is necessary for transformation, as discussed previ-
ously [162, 260].
The expression of a number of lncRNAs can also be modu-
lated by E7. Contrasting reports exist on the effect of E7 on 
expression of the HOX transcript antisense intergenic RNA 
(HOTAIR): one study indicated that HOTAIR was highly 
expressed in cervical cancer tissue and cell lines [261], whilst 
others suggest HOTAIR is in fact downregulated [262, 263]. 
A physical interaction between HPV16 E7 and HOTAIR has 
also been reported [262]. This is hypothesized to disrupt 
normal HOTAIR function by impeding its binding to the 
Polycomb repressive complex 2 (PRC2) and the histone lysine 
demethylase KDM1A, ultimately leading to the derepression 
of target genes. Other lncRNAs reportedly regulated by E7 
include LINC01101 and LINC00277, both of which demon-
strate low expression levels in cervical cancer specimens and 
are upregulated after siRNA silencing of E7 [264].
Interestingly, E7 may also act cooperatively with E6 to modu-
late lncRNA activity. Expression of thymopoietin pseudogene 
2 (TMPOP2) was found to be upregulated in an oncoprotein- 
dependent manner in HPV+ cervical cancer cells as well as 
in HPV16 E6/E7 expressing keratinocytes [263, 265]. Deple-
tion of TMPOP2 resulted in a decrease in proliferation due 
to arrest in G1 phase and a reduction in cyclin E and CDK2 
expression [265]. Further, the oncoproteins have also been 
implicated in upregulating expression of the widely- studied 
metastasis associated lung adenocarcinoma transcript 1 
(MALAT1) lncRNA [266]. Dysregulation of lncRNAs by 
HPV may also contribute towards delaying the onset of 
differentiation in keratinocytes: expression of HPV16 E6 and 
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E7 in primary keratinocytes resulted in increased expression 
of differentiation antagonizing non- protein coding RNA 
(DANCR), whilst tissue differentiation- inducing non- protein 
coding RNA (TINCR) expression was suppressed [263]. High 
DANCR expression has similarly been reported in cervical 
cancer tissue, and depletion of DANCR significantly inhibited 
proliferation, migration and invasion, whilst siRNA knock-
down of TINCR promoted cell growth [267, 268].
Finally, emerging evidence indicates that E7 may also 
dysregulate the expression of circRNAs. These are a collec-
tion of covalently closed ncRNAs produced by a unique 
splicing mechanism and function most commonly as 
sponges for miRNAs and in regulating gene transcrip-
tion [269]. Microarray analysis demonstrated that upon 
E7 knockdown in CaSki cells, over 500 circRNAs were 
found to be altered in expression level [270]. However, 
the functional significance of this is yet to be understood. 
Other studies have also identified differentially expressed 
circRNAs in cervical cancer tissue, but whilst they have 
been linked to proliferation and cancer progression, it is 
as yet unclear whether changes in their expression are a 
direct result of oncoprotein activity [271–273]. Interest-
ingly, HPV16 has been demonstrated to express its own 
circRNAs, one of which contains the entire E7 ORF and is 
hence termed circE7 [274]. Somewhat surprisingly, rather 
than functioning as a miRNA sponge, circE7 was found to 
be required for optimal E7 protein expression and circE7 
depletion significantly impeded the proliferation of HPV+ 
cervical cancer cells [274].
CONCLUSIONS
The HPV oncoproteins E5, E6 and E7 have evolved to hijack 
many host signalling pathways in order to generate a cellular 
environment conducive for virus replication. This includes 
the widely studied functions of E6 and E7 in targeting p53 
and pRb, respectively, for proteasomal degradation. These, 
together with the other oncoprotein functions discussed 
in this review, act to stimulate proliferation, delay differ-
entiation, inhibit apoptosis and evade immune detection. 
An undesired consequence of this is the acquisition of 
mutations in cellular genes, particularly in the context of 
dysregulated oncoprotein expression, which can facilitate 
transformation. Although much progress has been made 
in understanding the host pathways modulated by HPV, 
novel mechanisms continue to be elucidated. Gaining a 
thorough understanding of the cellular proteins and path-
ways subverted by HPV during infection, and in particular 
during carcinogenesis, will aid in the development of novel 
therapeutic agents.
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